Flemming Ørnskov

Chief Executive Officer (Chair of Executive Committee), Galderma

Search every verified Flemming Ørnskov interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Flemming Ørnskov, CEO of Galderma, has discussed his leadership approach and the company’s strategy in several podcast interviews. He stated that he runs Galderma as if it were a public company, focusing on financial rigor and compliance. Ørnskov said the company has nearly doubled its R&D investments and launched 22 new products or formulations in a single year. He highlighted two biologic programs: nemolizumab, an IL-31 inhibitor, and QM1114, an in-house developed botulinum toxin A, which he said showed a median onset of two days and duration up to six months in phase three studies. Ørnskov noted that the company maintained supply across its four manufacturing sites during the COVID-19 pandemic. Ørnskov has described his leadership approach as avoiding procrastination and sticking to a clear plan, citing the transformation of Galderma’s logo, website, and operations. He said he runs the company as if it were publicly listed, despite not needing IPO proceeds for funding. He emphasized the company’s focus on dermatology, stating that the company aims to "advance dermatology for every skin story" through innovation. Ørnskov, a former physician, said he draws on his medical background and described his role as being "all in" and focused on delivering for the team. He also noted that the company has increased investment in R&D and training for customer-facing staff.